{"entity":{"id":"li-zonghai","kind":"person","name":"Zonghai Li","aka":["李宗海"],"tldr":"Zonghai Li moved CAR-T therapy from blood cancers into stomach cancer, founding CARsgen and developing satri-cel, the first CAR-T approved for a solid tumour.","summary":"At the Shanghai Cancer Institute Li developed GPC3-directed CAR-T for liver cancer and the Claudin 18.2 CAR-T CT041, whose phase 1 results (Nature Medicine 2022) and randomised phase 2 trial in gastric cancer led to NMPA approval as satricabtagene autoleucel in 2025; CARsgen's fully human BCMA CAR-T zevorcabtagene autoleucel was approved in 2024. He founded CARsgen in 2014 and listed it in Hong Kong in 2021.","asOf":"2026-09-10","links":[{"label":"CARsgen Therapeutics","url":"https://www.carsgen.com/en/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20Z%5BAuthor%5D%20claudin18.2%20CAR-T%20gastric"}],"tags":["china"],"related":[],"cancers":["gastric","hcc","multiple-myeloma"],"sections":[],"technologies":["car-t"],"targets":["cldn18-2","gpc3","bcma"],"drugs":["satricabtagene-autoleucel","zevorcabtagene-autoleucel"],"companies":["carsgen"],"institutions":["renji-hospital"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Founder, Chairman and CEO, CARsgen Therapeutics; Professor, Shanghai Cancer Institute, Renji Hospital","institutionId":"renji-hospital","specialisms":["CAR-T for solid tumours","Claudin 18.2","GPC3","Antibody engineering"],"profiles":[{"label":"CARsgen Therapeutics","url":"https://www.carsgen.com/en/"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Li%20Z%5BAuthor%5D%20claudin18.2%20CAR-T%20gastric"}],"papers":[{"title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","journal":"Nature Medicine","year":2022,"doi":"10.1038/s41591-022-01800-8"}],"orcid":"0000-0003-2448-3636"},"route":"/people/li-zonghai/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"technology":[{"id":"car-t","kind":"technology","name":"CAR-T cell therapy","route":"/technologies/car-t/"}],"target":[{"id":"bcma","kind":"target","name":"BCMA","route":"/targets/bcma/"},{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"},{"id":"gpc3","kind":"target","name":"Glypican-3","route":"/targets/gpc3/"}],"drug":[{"id":"satricabtagene-autoleucel","kind":"drug","name":"Satricabtagene autoleucel","route":"/drugs/satricabtagene-autoleucel/"},{"id":"zevorcabtagene-autoleucel","kind":"drug","name":"Zevorcabtagene autoleucel","route":"/drugs/zevorcabtagene-autoleucel/"}],"company":[{"id":"carsgen","kind":"company","name":"CARsgen Therapeutics","route":"/companies/carsgen/"}],"institution":[{"id":"renji-hospital","kind":"institution","name":"Renji Hospital, Shanghai Jiao Tong University","route":"/institutions/renji-hospital/"}]}}